

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Smoore International Holdings Limited

思摩爾國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 06969)

**FINANCIAL UPDATE
FOR THE PERIOD ENDED 30 SEPTEMBER 2026**

This announcement is made by the board of directors (the “**Board**”) of Smoore International Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and based on the unaudited consolidated management accounts of the Company and its subsidiaries (collectively, the “**Group**”) for the three months ended 30 September 2026 (the “**Period**”).

EVE Energy Co., Limited (“**EVE Energy**”), one of the controlling shareholders of the Company listed on the Shenzhen Stock Exchange, is required to issue quarterly financial reports pursuant to the Rules Governing the Listing of Shares on the ChiNext Market of Shenzhen Stock Exchange. The quarterly financial reports of EVE Energy will include certain financial information which could be considered to be indicative of the Group’s total comprehensive income for the same period. The Company has decided that, in addition to the regulatory announcements of interim and annual financial results, the Company will also announce the Group’s total comprehensive income for first and third quarters of a financial year.

	Three Months Ended the Date Below					Nine Months Ended the Date Below		
	Unaudited (RMB Million)					Unaudited (RMB Million)		
	30 September 2026	30 June 2026	Quarter-on- quarter Change %	30 September 2025	Year-on- year Change %	30 September 2026	30 September 2025	Year-on- year Change %
Revenue	3,946.2	3,352.9	17.7%	4,196.8	−6.0%	11,155.1	10,210.1	9.3%
Corporate client oriented business	3,143.2	2,642.4	19.0%	3,430.7	−8.4%	9,053.0	8,169.7	10.8%
— Electronic vaping products and related technical services, and special purpose atomization products	2,651.1	2,276.6	16.4%	2,603.2	1.8%	7,451.8	6,996.2	6.5%
— Heat-not-burn products and technical services	396.5	297.6	33.2%	759.5	−47.8%	1,358.1	987.3	37.6%
— Inhalation therapy technical services	95.6	68.2	40.2%	68.0	40.6%	243.1	186.2	30.6%
Self-branded business	803.0	710.5	13.0%	766.1	4.8%	2,102.1	2,040.4	3.0%
— Electronic vaping products	791.7	695.5	13.8%	756.4	4.7%	2,068.2	2,000.1	3.4%
— Beauty atomization products	11.3	15.0	−24.7%	9.7	16.5%	33.9	40.3	−15.9%
Profit before tax	456.7	509.0	−10.3%	432.7	5.5%	1,329.2	1,131.4	17.5%
Profit for the Period	365.1	309.4	18.0%	316.9	15.2%	937.0	809.1	15.8%
Total comprehensive income	294.3	142.1	107.1%	284.2	3.6%	564.3	785.4	−28.2%
Add: Share-based payment expenses	87.1	100.2	−13.1%	127.3	−31.6%	271.8	372.5	−27.0%
Adjusted profit for the Period ¹	452.2	409.6	10.4%	444.2	1.8%	1,208.8	1,181.6	2.3%
Subtract: Loss for the Period of the inhalation therapy business	42.7	12.3	247.2%	74.5	−42.7%	175.1	167.1	4.8%
Adjusted profit for the Period, excluding inhalation therapy business ²	494.9	421.9	17.3%	518.7	−4.6%	1,383.9	1,348.7	2.6%

¹ Adjusted profit for the Period = Profit for the Period + Share-based payment expenses.

² Adjusted profit for the Period, excluding inhalation therapy business = Adjusted profit for the Period – Profit/loss for the Period of the inhalation therapy business.

During the Period, the Group recorded revenue of approximately RMB3,946.2 million, representing a quarter-on-quarter increase of approximately 17.7% and a year-on-year decline of approximately 6.0%.

Revenue from the corporate client oriented business was approximately RMB3,143.2 million during the Period, representing a quarter-on-quarter increase of approximately 19.0% and a year-on-year decline of approximately 8.4%.

During the Period, revenue from electronic vaping products and related technical services and special purpose atomization products amounted to approximately RMB2,651.1 million, representing a quarter-on-quarter increase of approximately 16.4% and a year-on-year increase of approximately 1.8%. The growth was mainly attributable to the solid performance of the U.S. market, where the Group commenced delivering flavoured electronic vaping products for a key customer during the Period. These new products have been launched in end-markets as scheduled.

During the Period, revenue from heat-not-burn (“**HNB**”) products and related technical services amounted to approximately RMB396.5 million, representing a quarter-on-quarter increase of approximately 33.2%. The Group established a collaboration with a new tobacco customer and commenced providing comprehensive HNB solutions to this customer during the Period. On a year-on-year basis, revenue from HNB products and related technical services decreased by approximately 47.8%, primarily attributable to the high comparison base arising from the commencement of large-scale shipments to a key customer in the corresponding period of last year.

During the Period, the Group’s inhalation therapy business recorded revenue of approximately RMB95.6 million, representing a quarter-on-quarter increase of approximately 40.2% and a year-on-year increase of approximately 40.6%. Revenue from Transpire Bio Inc. (“**Transpire**”), the Group’s inhalation therapy business platform, was primarily derived from technical services provided to corporate customers. The business progressed as scheduled during the Period. The Group continued to advance Transpire’s external equity financing with a view to unlocking its value.

During the Period, revenue from the Group’s self-branded business amounted to approximately RMB803.0 million, representing a quarter-on-quarter increase of approximately 13.0%, primarily benefiting from the successful launch and growing contribution of new products. On a year-on-year basis, revenue from the self-branded business increased by approximately 4.8%, primarily driven by continued market share gains for its self-branded electronic vaping products in key markets.

During the Period, profit for the Period amounted to approximately RMB365.1 million, representing a quarter-on-quarter increase of approximately 18.0% primarily driven by revenue and gross profit growth in (i) the electronic vaping business in the U.S. market; and (ii) the HNB business. On a year-on-year basis, profit for the Period increased by approximately 15.2%, primarily attributable to (i) an increase in gross profit driven by higher revenue from products with higher profit margins; and (ii) decreases in selling and distribution expenses and research and development expenses.

During the Period, excluding share-based payment expenses, adjusted profit for the Period amounted to approximately RMB452.2 million, representing a quarter-on-quarter increase of approximately 10.4% and a year-on-year increase of approximately 1.8%.

During the Period, adjusted profit for the Period, excluding inhalation therapy business amounted to approximately RMB494.9 million, representing a quarter-on-quarter increase of approximately 17.3% and a year-on-year decline of approximately 4.6%.

The information contained in this announcement is only based on the preliminary review on the unaudited consolidated management accounts of the Group, which have not been reviewed by the independent auditors. The aforesaid information may not be indicative of the financial performance of the Group for its full financial year. Shareholders and potential investors are advised not to place reliance on the aforesaid information and advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Smoore International Holdings Limited
Mr. Chen Zhiping
Chairman of the Board

Hong Kong, 12 October 2026

As at the date of this announcement, the Executive Directors are Mr. Chen Zhiping, Mr. Xiong Shaoming, Mr. Wang Guisheng and Ms. Wang Xin; the Non-executive Director is Ms. Jiang Min; and the Independent Non-executive Directors are Mr. Zhong Shan, Mr. Yim Siu Wing, Simon and Dr. Wang Gao.